FDA Grants Fast Track Designation to Kymera Therapeutics' KT-621 for Eosinophilic Asthma
The FDA has granted Fast Track designation to Kymera Therapeutics' (KYMR) KT-621 for the treatment of eosinophilic asthma. This designation may help accelerate the drug's development timeline. Additionally, Gilead Sciences has exercised its option to obtain global rights to Kymera's KT-200, a CDK2 degrader, and will pay a $45 million milestone payment.
Topics: Biotech Clinical Trials Drug Development Fast Track Designation FDA